could be successfully used in the proper drug delivery and treatment of cancer (Kural

and Gursoy 2011).

Lipopeptide NPs are among the strongest NPs for the exchange of specific siRNA

delivery in non-human primates and rodents. siRNA therapeutics are used for the

treatment of genetic disorders. Encoding of this siRNA on to the nanoparticle

structure of lipopeptide ensures its target drug delivery up to the point of genetic

disorder.

26.9

Limitations

The main limitation to the LP-NP molecules is about their stability which often leads

to the prevention of the aggregation process causing loss in their antibacterial

activity. The biological methods for NP-LP productions are still at a developing

stage; also it is hard to control and achieve the desired shape, size and controlled

dispersion in NP-LP production. Many different microorganisms have been success-

fully utilized for production of NP-LP particles (Ohadi et al. 2020), but impacts of

such microbes, synthesis conditions and growth media which are probably respon-

sible for their potent biological and physiochemical properties are still not under-

stood properly.

26.10 Future Perspectives and Conclusion

With the advent of new inventions and research in field of nanotechnology, the

concept of developing the nano-form of important biological molecules is possible

today. Many scientists consider it as the future of medicinal science. NP-based drugs

play significant roles in commercial development. LPs extracted from various

microbial and plant sources have many medical applications. Antimicrobial and

Fig. 26.2 General functions

of NP-LP molecules

26

Nanoparticle-Associated Lipopeptides: A New Class of Antimicrobials

491